PMID- 22070180
OWN - NLM
STAT- MEDLINE
DCOM- 20120424
LR  - 20211021
IS  - 1557-8992 (Electronic)
IS  - 1044-5463 (Print)
IS  - 1044-5463 (Linking)
VI  - 21
IP  - 6
DP  - 2011 Dec
TI  - Risperidone-related improvement of irritability in children with autism is not 
      associated with changes in serum of epidermal growth factor and interleukin-13.
PG  - 555-64
LID - 10.1089/cap.2010.0134 [doi]
AB  - Risperidone has been shown to improve serious behavioral problems in children 
      with autism. Here we asked whether risperidone-associated improvement was related 
      to changes in concentrations of inflammatory molecules in the serum of these 
      subjects. Seven molecules were identified as worthy of further assessment by 
      performing a pilot analysis of 31 inflammatory markers in 21 medication-free 
      subjects with autism versus 15 healthy controls: epidermal growth factor (EGF), 
      interferon-gamma (IFN-gamma), interleukin (IL)-13, IL-17, monocyte chemoattractant 
      protein-1 (MCP-1), IL-1 and IL-1-receptor antagonist. Serum concentrations of 
      these markers were then established in a different set of subjects that 
      participated in a double-blind, clinical trial and an expanded group of healthy 
      subjects. In the first analysis, samples obtained from subjects with autism at 
      baseline visits were compared to visits after 8-week treatment with placebo 
      (n=37) or risperidone (n=40). The cytokine concentrations remained stable over 
      the 8-week period for both risperidone and placebo groups. In the second 
      analysis, we explored further the differences between medication-free subjects 
      with autism (n=77) and healthy controls (recruited independently; n=19). Serum 
      levels of EGF were elevated in subjects with autism (median=103 pg/mL, n=75) in 
      comparison to healthy controls (75 pg/mL, n=19; p<0.05), and levels of IL-13 were 
      decreased in autism (median=0.8 pg/mL, n=77) in comparison to controls (9.8 
      pg/mL, n=19; p=0.0003). These changes did not correlate with standardized 
      measures used for a diagnosis of autism. In summary, risperidone-induced clinical 
      improvement in subjects with autism was not associated with changes in the serum 
      inflammatory markers measured. Whether altered levels of EGF and IL-13 play a 
      role in the pathogenesis or phenotype of autism requires further investigation.
FAU - Tobiasova, Zuzana
AU  - Tobiasova Z
AD  - Department of Immunobiology, New Haven, CT 06520, USA.
FAU - van der Lingen, Klaas H B
AU  - van der Lingen KH
FAU - Scahill, Lawrence
AU  - Scahill L
FAU - Leckman, James F
AU  - Leckman JF
FAU - Zhang, Yan
AU  - Zhang Y
FAU - Chae, Wookjin
AU  - Chae W
FAU - McCracken, James T
AU  - McCracken JT
FAU - McDougle, Christopher J
AU  - McDougle CJ
FAU - Vitiello, Benedetto
AU  - Vitiello B
FAU - Tierney, Elaine
AU  - Tierney E
FAU - Aman, Michael G
AU  - Aman MG
FAU - Arnold, L Eugene
AU  - Arnold LE
FAU - Katsovich, Liliya
AU  - Katsovich L
FAU - Hoekstra, Pieter J
AU  - Hoekstra PJ
FAU - Volkmar, Fred
AU  - Volkmar F
FAU - Bothwell, Alfred L M
AU  - Bothwell AL
FAU - Kawikova, Ivana
AU  - Kawikova I
LA  - eng
GR  - N01MH70009/MH/NIMH NIH HHS/United States
GR  - AS1474/Autism Speaks/United States
GR  - N01MH80011/MH/NIMH NIH HHS/United States
GR  - N01MH70010/MH/NIMH NIH HHS/United States
GR  - MH01805/MH/NIMH NIH HHS/United States
GR  - N01MH70001/MH/NIMH NIH HHS/United States
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20111109
PL  - United States
TA  - J Child Adolesc Psychopharmacol
JT  - Journal of child and adolescent psychopharmacology
JID - 9105358
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Interleukin-13)
RN  - 62229-50-9 (Epidermal Growth Factor)
RN  - L6UH7ZF8HC (Risperidone)
SB  - IM
MH  - Adolescent
MH  - Anti-Inflammatory Agents/pharmacology
MH  - Antipsychotic Agents/pharmacology/therapeutic use
MH  - Autistic Disorder/blood/*drug therapy/psychology
MH  - Biomarkers/blood
MH  - Child
MH  - Child, Preschool
MH  - Double-Blind Method
MH  - Epidermal Growth Factor/blood/*drug effects
MH  - Female
MH  - Humans
MH  - Inflammation Mediators/blood
MH  - Interleukin-13/blood
MH  - Irritable Mood/*drug effects/physiology
MH  - Male
MH  - Risperidone/*pharmacology/*therapeutic use
PMC - PMC3279715
EDAT- 2011/11/11 06:00
MHDA- 2012/04/25 06:00
PMCR- 2012/12/01
CRDT- 2011/11/11 06:00
PHST- 2011/11/11 06:00 [entrez]
PHST- 2011/11/11 06:00 [pubmed]
PHST- 2012/04/25 06:00 [medline]
PHST- 2012/12/01 00:00 [pmc-release]
AID - 10.1089/cap.2010.0134 [pii]
AID - 10.1089/cap.2010.0134 [doi]
PST - ppublish
SO  - J Child Adolesc Psychopharmacol. 2011 Dec;21(6):555-64. doi: 
      10.1089/cap.2010.0134. Epub 2011 Nov 9.